BiotechTube

ATH-1017

Phase 2/3Terminated
0 watching 0 views this week⚡ Active
57
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alzheimer Disease

Conditions

Alzheimer Disease

Trial Timeline

Jun 30, 2021 → Oct 23, 2024

NCT ID
NCT04886063

About ATH-1017

ATH-1017 is a phase 2/3 stage product being developed by LeonaBio for Alzheimer Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT04886063. Target conditions include Alzheimer Disease.

Hype Score Breakdown

Clinical
22
Activity
15
Company
2
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT04886063Phase 2/3Terminated

Competing Products

20 competing products in Alzheimer Disease

See all competitors
ProductCompanyStageHype Score
[18F]NAV4694Navidea BiopharmaceuticalsPhase 2
44
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
40
LY450139 + PlaceboEli LillyPhase 3
77
Solanezumab + PlaceboEli LillyPhase 3
77
LY450139 dihydrate + placeboEli LillyPhase 2
52
Zagotenemab + PlaceboEli LillyPhase 2
52
Donanemab + Placebo + LY3202626Eli LillyPhase 2
52
Donanemab + PlaceboEli LillyPhase 3
77
GSK4527226AlectorPhase 2
44
AL002 + PlaceboAlectorPhase 2
44
GSK4527226AlectorPhase 2
44
AL002AlectorPhase 2
44
Solanezumab + PlaceboEli LillyPhase 3
77
donanemabEli LillyPhase 2
52
ATH-1017 + PlaceboLeonaBioPhase 2/3
57
ATH-1017 + PlaceboLeonaBioPhase 2
44
NDX-1017 + PlaceboLeonaBioPhase 1
25
simufilamCassava SciencesPhase 2
44
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125Cassava SciencesPhase 1
25
Placebo oral tablet + Simufilam 100 mg tablet + Simufilam 50 mg oral tabletCassava SciencesPhase 2
44

Other Products from LeonaBio

ATH-1017 + PlaceboPhase 2/3
57
ATH-1017 + PlaceboPhase 2
44
ATH-1017 + PlaceboPhase 2
44
ATH-1105 + PlaceboPhase 1
25
[14C]-FosgonimetonPhase 1
25